Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7547-7552

  Monica, Valentina ^a   Scagliotti, Giorgio V ^a   Ceppi, Paolo ^a   Righi, Luisella ^a   Cambieri, Alberto ^a   Lo Iacono, Marco ^a   Saviozzi, Silvia ^a   Volante, Marco ^a   Novello, Silvia ^a   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MARKER; MESSENGER RNA; PROTEIN; THYMIDYLATE SYNTHASE; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR E2F1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY;

EID: 73349084270     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1641     Document Type: Article

References (25)

1. Travis WD, Brambilla E, Müller-Hermelink HK, Harris C. World Health Organisation Classification of Tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2004.
2. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-81.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51.
4. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). Presented at the 44th Annual American Society of Clinical Oncology Meeting, Orlando, FL, May 31, 2009. J Clin Oncol 2009;27: 18s (June 20 supplement), CRA8000.
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63.
6. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-12.
7. Peng G, Zinner R, Wang Y, et al. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two Phase II trials. Presented at the 44th Annual ASCO Meeting, Chicago, IL, 2 June, 2008. J Clin Oncol 2008;26:15s (May 20 supplement), 8096.
8. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96.
9. Ceppi P, Volante M, Ferrero A, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008;14:1059-64.
10. Ma T, Zhu ZG, Ji YB, et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2¡ä- deoxyuridine. World J Gastroenterol 2004;10:172-6.
11. Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997;15:1923-31.
12. Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-13.
13. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-8.
14. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-56.
15. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-17.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ÄÄ C(T)) method. Methods 2001;25:402-8.
17. Hashimoto H, Ozeki Y, Sato M, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006;106:1595-601.
18. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-73.
19. Huang CL, Liu D, Nakano J, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 2007;13:6938-46.
20. Gridelli C, Kaukel E, Gregorc V, et al. Singleagent pemetrexed or sequential pemetrexed/ gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007;2:221-9.
21. 1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
22. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998;58:4292-6.
23. BorczukAC,Gorenstein L,Walter KL, AssaadAA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003;163:1949-60.
24. Gadd M, Pisc C, Branda J, et al. Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution. Cancer Res 2001;61:8811-9.
25. Le Francois BG, Maroun JA, Birnboim HC. Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F. Br J Cancer 2007;97: 1242-50.